Member Info for EarlofAim

why UK moved from Manufacturing clothing to High tech Industries? because manufacturing is hard work with little pay.
30p per mask and Peeps making reference to NCYT t??hmmm
needs to be investigated, research

manufacturing is not working in the UK since 1980s, China have cheap labour, and Nottingham can't pay below national average and attract good workers.
I see this project as a loss making entity.
Unless sell patent to Chinese company and get 5p per mask without any hassle or cost.

IMO

not easy task to design, make, manufacture, sell
OK Hype is fine to an extent, However Reality for Investors is a a huge problem.
to manufacture huge amounts of masks will need lots of resources like Raw materials,
huge complex Machinery,
manpower

logistics and Distribution, then the big question is,
will there be a demand for 5 Layer mask or 3 layer ones

current 3 layer is uncomfortable for long use, what will happen to five layers.

some really tough reality checks needs to be done

Reply

OK Hype is fine to an extent, However Reality for Investors is a a huge problem.
to manufacture huge amounts of masks will need lots of resources like Raw materials,
huge complex Machinery,
manpower

logistics and Distribution, then the big question is,
will there be a demand for 5 Layer mask or 3 layer ones

current 3 layer is uncomfortable for long use, what will happen to five layers.

some really tough reality checks needs to be done

Pro axis with lung disease diagnosis, priceless.
North America has one of the high level of Lung diseases due to Covid19.

this is the right place for the right diagnosis company
GLA

to come up with an idea is good, however to produce it in massive numbers like millions is a huge challenge

watch this video guys

https://youtu.be/Rpfixy1MH7k

this video will highlight the enormous amount of work and investment needs to have a mega mask production facility.

Google "mask manufacturers"
https://youtu.be/Rpfixy1MH7k

https://youtu.be/Rpfixy1MH7k

looks like website doesn't link up

'Google, "Toop directors Talk"
and read Q 7

worth researching

Read Q7, CEO talks about government contracts!

https://www.*************.net/toople-qa-optimistic-about-future-prospects-lontoop/

https://telecoms.com/503027/uk-government-pumps-5-billion-into-broadband-sector/#:~:text=In%20the%20first%20budget%20of,a%20major%20public%20spending%20spree.&text=The%20%C2%A35%20billion%20of,the%20hardest%20to%20reach%20places.

worth researching #Toop

worth a look at this.
chancellor Riski Sunaks budget

https://www.spglobal.com/marketintelligence/en/news-insights/latest-news-headlines/uk-government-pledges-163-5b-for-broadband-investment-163-5b-for-covid-19-response-57530802#:~:text=The%20U.K.%20government%20unveiled%20plans,Scotland%2C%20Wales%20and%20Northern%20Ireland.

wait guys look at this huge potential here,
CEO already done this with Telecom giant Talk Talk.
CEO said to make this into £100M Mcap company

seen this many times on other stocks.
momentarily the sp has different mcap, but eventually gets corrected.
either Canada drops to UK level or UK rises to Canada level. it will happen soon.

BOD
have no choice but to get this done as no numeration for them until deals done

fantastic opportunity here

Dr Blackwell

Give us some update on longcovid and the fact NXP002 have a good treatment, potentially world class as seen results on 3 Dec 2018

Long covid is a real threat to over 500,000 peoples lives directly. in directy it has huge implications for greater population.

NXP002 has been the best option for long damage treatment.
hope NUFORMIX is well placed to take this advantage

skakadenus

sorry to hear that,
I think this is the beginning of something special for NUFORMIX.
not every discovery has massive potentials, however with this and the covid19 long covid19 sufferers, this is right treatment for the patients.

online the news is spreading about long Covid.

we have Newcastle University to help with this.

Newcastle University use a highly innovative new human tissue model, which has the potential to become the new gold standard for pre-clinical studies. These findings are important for IPF patients and show our NXP002 programme can play an important role in improving on current treatment options and extending both life and its quality."



Nuformix will now seek to optimise delivery of a candidate within its NXP002 programme to maximise efficacy and tolerability using its patented novel drug forms before moving into patient studies.

Cambridge, UK, 3rd December 2018: Nuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, announces results from the completion of its innovative pre-clinical trial for its NXP002 fibrosis programme in human idiopathic pulmonary fibrosis ('IPF') against standard of care[1].



Multi-patient tissue studies were performed in partnership with Newcastle University, UK using a leading-edge human tissue trial model that closely replicates the clinical disease:



· Data demonstrates NXP002 candidates strongly inhibit fibrosis ex-vivo, even in very severely fibrotic patient tissue, giving strong support for treating IPF and other fibrotic lung conditions

· In addition, NXP002 demonstrated specific action measured against key inflammatory targets

· NXP002 out-performed current standard of care treatment, Esbriet ® (pirfenidone)